-
公开(公告)号：US20110312891A1
公开(公告)日：2011-12-22
申请号：US13000130
申请日：2009-06-29
IPC分类号： A61K38/17 , A61P19/08 , C12N5/0775 , C07K14/47 , C12N5/071
CPC分类号： C07K14/78
摘要： Isolated active compound of a naturally occurring fraction of Enamel Matrix Derivatives (EMD), having at least one of each two N-terminal polypeptide fragments of amelogenin, which are at least 95% identical to an amino acid sequence as shown in SEQ. ID. No:1 and/or 2. The invention relates to the use of said isolated active compound of a fraction and/or of the fraction itself, and/or the at least one of each two polypeptide fragments for use as a medicament and/or for the manufacture of a pharmaceutical composition for a variety of different medical indications such as inducing and/or promoting cementogenesis, bone growth and/or binding between parts of living mineralised tissue, for bonding of a piece of living mineralised tissue to a bonding site on a piece of other living tissue, for endorsing binding between hard tissues, for inducing regeneration of dentin, and/or for filling a mineralized wound cavity and/or tissue defect following from a procedure and/or trauma.
摘要翻译： 具有至少与氨基酸序列至少95％相同的釉质蛋白的两个N末端多肽片段中至少一个的釉质基质衍生物（EMD）的天然存在部分的分离的活性化合物。 ID。 本发明涉及所述分离的活性成分和/或级分本身的分离活性化合物和/或每两种多肽片段中的至少一种用作药物和/或 用于制造用于各种不同医学适应症的药物组合物，例如诱导和/或促进活的矿化组织的部分之间的骨水泥生成，骨生长和/或结合，用于将一块活的矿化组织粘合到粘合部位上 用于在手术和/或创伤之后识别硬组织之间的结合，用于诱导牙质的再生和/或用于填充矿化的伤口腔和/或组织缺损的一块其它活组织。
-
公开(公告)号：US20120309685A1
公开(公告)日：2012-12-06
申请号：US13505122
申请日：2010-10-29
申请人： P. Mark Bartold , Peter S. Zilm , Corinna Mauth , Ruzica Ranevski
发明人： P. Mark Bartold , Peter S. Zilm , Corinna Mauth , Ruzica Ranevski
CPC分类号： A61K38/1709 , A61K8/64 , A61K8/981 , A61K2800/654 , A61L27/227 , A61L27/54 , A61L2300/252 , A61L2300/412 , A61Q11/00
摘要： Pharmaceutical, dental and/or cosmetic composition consisting of purified Enamel Matrix Derivative (EMD) proteins which have a molecular weight between 1 and 55 kDa, formulated in a suitable pharmaceutical carrier. The composition is depleted of proteins which have a molecular weight between 56 and 160 kDa and an iso-electric point between 3-10. The purified Enamel Matrix Derivative (EMD) proteins are depleted of proteinase inhibitors, such as α1-antichymotrypsin and/or Fetuin A. The composition is preferably used for promoting and/or inducing regeneration of hard tissue, tissue mineralization, bone growth and/or bone regrowth, regeneration of dentin, cementogenesis, and/or binding between parts of living mineralized tissue, for bonding of a piece of living mineralized tissue to a bonding site on a piece of other living tissue, for endorsing binding between hard tissues, and/or for filling a mineralized wound cavity and/or tissue defect following from a procedure and/or trauma.
摘要翻译： 由分子量为1至55kDa的纯化的釉质基质衍生物（EMD）蛋白质组成的药物，牙科和/或化妆品组合物，配制在合适的药物载体中。 该组合物耗尽了分子量在56至160kDa之间且等电点在3-10之间的蛋白质。 纯化的釉质基质衍生物（EMD）蛋白质耗尽蛋白酶抑制剂，例如α1-抗胰凝乳蛋白酶和/或胎儿蛋白A.该组合物优选用于促进和/或诱导硬组织再生，组织矿化，骨生长和/或 骨再生，牙本质的再生，水泥生成和/或活的矿化组织的部分之间的结合，用于将一块活的矿化组织结合到一块其他生物体组织上的结合位点，用于支持硬组织之间的结合和/ 或用于在手术和/或创伤之后填充矿化伤口腔和/或组织缺损。
-
公开(公告)号：US08466101B2
公开(公告)日：2013-06-18
申请号：US13505122
申请日：2010-10-29
申请人： P. Mark Bartold , Peter S. Zilm , Corinna Mauth , Ruzica Ranevski
发明人： P. Mark Bartold , Peter S. Zilm , Corinna Mauth , Ruzica Ranevski
CPC分类号： A61K38/1709 , A61K8/64 , A61K8/981 , A61K2800/654 , A61L27/227 , A61L27/54 , A61L2300/252 , A61L2300/412 , A61Q11/00
摘要： Pharmaceutical, dental and/or cosmetic composition consisting of purified Enamel Matrix Derivative (EMD) proteins which have a molecular weight between 1 and 55 kDa, formulated in a suitable pharmaceutical carrier. The composition is depleted of proteins which have a molecular weight between 56 and 160 kDa and an iso-electric point between 3-10. The purified Enamel Matrix Derivative (EMD) proteins are depleted of proteinase inhibitors, such as α1-antichymotrypsin and/or Fetuin A. The composition is preferably used for promoting and/or inducing regeneration of hard tissue, tissue mineralization, bone growth and/or bone regrowth, regeneration of dentin, cementogenesis, and/or binding between parts of living mineralized tissue, for bonding of a piece of living mineralized tissue to a bonding site on a piece of other living tissue, for endorsing binding between hard tissues, and/or for filling a mineralized wound cavity and/or tissue defect following from a procedure and/or trauma.
摘要翻译： 由分子量为1至55kDa的纯化的釉质基质衍生物（EMD）蛋白质组成的药物，牙科和/或化妆品组合物，配制在合适的药物载体中。 该组合物耗尽了分子量在56至160kDa之间且等电点在3-10之间的蛋白质。 纯化的釉质基质衍生物（EMD）蛋白质耗尽蛋白酶抑制剂，例如α1-抗胰凝乳蛋白酶和/或胎儿蛋白A.该组合物优选用于促进和/或诱导硬组织再生，组织矿化，骨生长和/或 骨再生，牙本质的再生，水泥生成和/或活的矿化组织的部分之间的结合，用于将一块活的矿化组织结合到一块其他生物体组织上的结合位点，用于支持硬组织之间的结合和/ 或用于在手术和/或创伤之后填充矿化伤口腔和/或组织缺损。
-
-
搜索结果
3 条记录 (耗时 0.021 秒)
